Champions Oncology Inc (CSBR) Gross Profit Margin starting from the first quarter 2026 to first quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Champions Oncology Inc   (NASDAQ: CSBR)


Champions Oncology Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CSBR Gross Profit Margin (Jul 31 2026)
Q1 		(Apr 30 2026)
Q4 		(Jan 31 2026)
Q3 		(Oct 31 2025)
Q2 		(Jul 31 2025)
Q1
Y / Y Revenue Change 8.84 %
Seq. Revenue Change 10.09 %
Revenue In Millions $15.23
Gross Profit Margin 50.54 %
Gross Profit Margin Total Ranking # 1972
Gross Profit In Millions $7.70
Y / Y Gross Profit Change 28.3 %
Seq. Gross Profit Change 9.55 %


Commenting First Quarter 2026 Gross Profit Margin
Champions Oncology Inc has managed to improve its Revenue sequentially to $15.23 millions by 10.09 % faster than Gross Profit increase of 9.55 % to $7.70 millions, this led to contraction in Gross Profit Margin to 50.54 %, but the Champions Oncology Inc I. Quarter Gross Profit Margin remained above company average rate of 47.52%.


Observing first quarter 2026 results within Biotechnology & Pharmaceuticals industry 36 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 1659 to 1972.
Learn about Gross Margin
CSBR's Gross Profit Margin first quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 347
Overall # 1962

Gross Profit Margin Statistics
High Average Low
61.17 % 47.52 % 34.7 %
(Jan 31 2025)   (Jan 31 2024)


CSBR Gross Income Trends • More of CSBR's Profitabilty Ratios • CSBR Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
CSBR's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
CSBR's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for CSBR's Competitors
Gross Profit Margin Profit Margin for Champions Oncology Inc 's Suppliers
Gross Profit Margin Profit Margin for CSBR's Customers

You may also want to know
CSBR's Annual Growth Rates CSBR's Profitability Ratios CSBR's Asset Turnover Ratio CSBR's Dividend Growth
CSBR's Roe CSBR's Valuation Ratios CSBR's Financial Strength Ratios CSBR's Gross Profit Growth
CSBR's Roa CSBR's Inventory Turnover Ratio CSBR's Growth Rates CSBR's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jul 31 2026, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginJul 31 2026 MRQ Gross ProfitJul 31 2026 MRQ Revenue
Immunitybio inc   99.42 %$ 50.942  Millions$ 51.240  Millions
Immunocore Holdings Plc  99.06 %$ 114.839  Millions$ 115.927  Millions
Biocryst Pharmaceuticals Inc   98.24 %$ 214.410  Millions$ 218.250  Millions
Neurocrine Biosciences Inc   97.58 %$ 935.800  Millions$ 959.000  Millions
Denali Therapeutics Inc   97.42 %$ 3.511  Millions$ 3.604  Millions
Exelixis Inc   96.71 %$ 608.033  Millions$ 628.690  Millions
Lenz Therapeutics Inc   94.90 %$ 5.206  Millions$ 5.486  Millions
Alpha Cognition Inc.  93.58 %$ 5.702  Millions$ 6.093  Millions
Tarsus Pharmaceuticals Inc   93.03 %$ 161.799  Millions$ 173.912  Millions
Ginkgo Bioworks Holdings Inc   91.47 %$ 18.437  Millions$ 20.156  Millions
Halozyme Therapeutics Inc   83.54 %$ 401.828  Millions$ 480.999  Millions
Gilead Sciences Inc   79.76 %$ 6,224.000  Millions$ 7,803.000  Millions
Pelthos Therapeutics Inc   76.86 %$ 11.993  Millions$ 15.603  Millions
Novavax inc   74.87 %$ 42.452  Millions$ 56.698  Millions
Vericel Corporation  72.82 %$ 56.402  Millions$ 77.457  Millions
Amgen Inc   72.04 %$ 7,243.000  Millions$ 10,054.000  Millions
Adaptive Biotechnologies Corporation  71.82 %$ 51.388  Millions$ 71.553  Millions
Coherus Oncology inc   70.35 %$ 10.065  Millions$ 14.307  Millions
Adma Biologics Inc   69.36 %$ 86.277  Millions$ 124.395  Millions
Bio techne Corp  65.82 %$ 211.394  Millions$ 321.192  Millions
Protalix Biotherapeutics inc   60.99 %$ 12.134  Millions$ 19.896  Millions
Elutia Inc   59.62 %$ 1.447  Millions$ 2.427  Millions
Pluri Inc   58.51 %$ 0.196  Millions$ 0.335  Millions
Xtant Medical Holdings Inc   57.88 %$ 13.330  Millions$ 23.031  Millions
Iovance Biotherapeutics inc   56.10 %$ 55.718  Millions$ 99.313  Millions
Autolus Therapeutics Plc  55.20 %$ 25.221  Millions$ 45.689  Millions
Repligen Corp  53.91 %$ 110.037  Millions$ 204.128  Millions
Twist Bioscience Corporation  52.76 %$ 62.454  Millions$ 118.376  Millions
Scilex Holding Company  51.88 %$ 3.965  Millions$ 7.642  Millions
Champions Oncology Inc   50.54 %$ 7.698  Millions$ 15.232  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.